Medtronic (MDT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended October 2025, Medtronic (MDT) reported revenue of $8.96 billion, up 6.6% over the same period last year. EPS came in at $1.36, compared to $1.26 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $8.86 billion, representing a surprise of +1.11%. The company delivered an EPS surprise of +3.82%, with the consensus EPS estimate being $1.31.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Medtronic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- U.S. Revenue: $4.52 billion versus the three-analyst average estimate of $4.53 billion. The reported number represents a year-over-year change of +4.9%.Net Sales- International: $4.45 billion versus $4.33 billion estimated by three analysts on average.Net Sales- ROW- Cardiovascular- Structural Heart & Aortic: $566 million versus $548.63 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +15% change.Net Sales- ROW- Cardiovascular- Cardiac Rhythm & Heart Failure: $905 million versus the two-analyst average estimate of $866.81 million.Net Sales- World Wide Revenue- Cardiovascular: $3.44 billion versus $3.37 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.Net Sales- World Wide Revenue- Diabetes: $757 million versus $749.91 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10.4% change.Net Sales- World Wide Revenue- Medical Surgical: $2.17 billion compared to the $2.37 billion average estimate based on six analysts. The reported number represents a change of +2% year over year.Net Sales-World Wide: $8.96 billion compared to the $8.85 billion average estimate based on six analysts.Net Sales- World Wide Revenue- Neuroscience: $2.56 billion compared to the $2.49 billion average estimate based on six analysts. The reported number represents a change of +4.5% year over year.Net Sales- World Wide Revenue- Neuroscience- Neuromodulation: $520 million compared to the $510.92 million average estimate based on five analysts. The reported number represents a change of +8.3% year over year.Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies: $1.3 billion versus $1.3 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change.Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular: $655 million versus $663.24 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1.9% change.View all Key Company Metrics for Medtronic here>>>Shares of Medtronic have returned +0.4% over the past month versus the Zacks S&P 500 composite's +0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks